Stem definition | Drug id | CAS RN |
---|---|---|
calcium-sensing receptors (CaSR) agonists | 647 | 226256-56-0 |
Dose | Unit | Route |
---|---|---|
60 | mg | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 0.10 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 0.10 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 7.19 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 20 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 17.60 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 18.30 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.05 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 19.90 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Oct. 22, 2004 | EMA | ||
March 8, 2004 | FDA | AMGEN |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Hospitalisation | 8523.27 | 22.01 | 2557 | 24047 | 65380 | 50513140 |
Product dose omission issue | 6899.87 | 22.01 | 2810 | 23794 | 181028 | 50397492 |
Laboratory test abnormal | 6124.59 | 22.01 | 1572 | 25032 | 21636 | 50556884 |
Adverse drug reaction | 1286.00 | 22.01 | 611 | 25993 | 54611 | 50523909 |
Intentional product misuse | 895.27 | 22.01 | 453 | 26151 | 46281 | 50532239 |
Blood parathyroid hormone increased | 844.88 | 22.01 | 213 | 26391 | 2641 | 50575879 |
Blood parathyroid hormone abnormal | 478.18 | 22.01 | 85 | 26519 | 130 | 50578390 |
Hospice care | 339.38 | 22.01 | 124 | 26480 | 5648 | 50572872 |
Arteriovenous fistula site complication | 322.26 | 22.01 | 70 | 26534 | 423 | 50578097 |
Adverse event | 253.94 | 22.01 | 199 | 26405 | 43564 | 50534956 |
Living in residential institution | 248.37 | 22.01 | 56 | 26548 | 411 | 50578109 |
Calciphylaxis | 225.77 | 22.01 | 75 | 26529 | 2563 | 50575957 |
Hypocalcaemia | 223.89 | 22.01 | 152 | 26452 | 26664 | 50551856 |
Death | 219.27 | 22.01 | 509 | 26095 | 324870 | 50253650 |
Blood calcium increased | 208.77 | 22.01 | 95 | 26509 | 7624 | 50570896 |
Rehabilitation therapy | 208.66 | 22.01 | 60 | 26544 | 1253 | 50577267 |
Decreased appetite | 199.51 | 22.01 | 369 | 26235 | 200554 | 50377966 |
Hypophagia | 184.81 | 22.01 | 137 | 26467 | 27591 | 50550929 |
Nausea | 180.11 | 22.01 | 788 | 25816 | 704610 | 49873910 |
Malaise | 179.67 | 22.01 | 481 | 26123 | 335051 | 50243469 |
Transplant | 165.28 | 22.01 | 43 | 26561 | 607 | 50577913 |
Blood calcium decreased | 148.60 | 22.01 | 107 | 26497 | 20599 | 50557921 |
Blood calcium abnormal | 147.77 | 22.01 | 44 | 26560 | 1042 | 50577478 |
Renal transplant | 147.00 | 22.01 | 45 | 26559 | 1174 | 50577346 |
Vomiting | 136.02 | 22.01 | 539 | 26065 | 460219 | 50118301 |
Blood parathyroid hormone decreased | 130.15 | 22.01 | 67 | 26537 | 7047 | 50571473 |
Parathyroid tumour benign | 124.14 | 22.01 | 34 | 26570 | 590 | 50577930 |
Parathyroidectomy | 122.60 | 22.01 | 28 | 26576 | 219 | 50578301 |
Unevaluable investigation | 122.55 | 22.01 | 21 | 26583 | 22 | 50578498 |
Nephrogenic systemic fibrosis | 119.41 | 22.01 | 54 | 26550 | 4268 | 50574252 |
Fatigue | 108.57 | 22.01 | 128 | 26476 | 707473 | 49871047 |
Peritonitis bacterial | 100.28 | 22.01 | 49 | 26555 | 4612 | 50573908 |
Arthralgia | 90.40 | 22.01 | 60 | 26544 | 438642 | 50139878 |
Abdominal discomfort | 90.14 | 22.01 | 297 | 26307 | 231344 | 50347176 |
Hungry bone syndrome | 89.00 | 22.01 | 18 | 26586 | 72 | 50578448 |
Blood phosphorus increased | 86.68 | 22.01 | 37 | 26567 | 2545 | 50575975 |
Rheumatoid arthritis | 86.39 | 22.01 | 5 | 26599 | 202545 | 50375975 |
Hypercalcaemia | 84.19 | 22.01 | 81 | 26523 | 23271 | 50555249 |
Brown tumour | 80.54 | 22.01 | 15 | 26589 | 34 | 50578486 |
Gastrointestinal tube insertion | 79.65 | 22.01 | 27 | 26577 | 982 | 50577538 |
Mastication disorder | 73.70 | 22.01 | 30 | 26574 | 1830 | 50576690 |
Pyrexia | 73.02 | 22.01 | 56 | 26548 | 380147 | 50198373 |
Pain | 71.45 | 22.01 | 122 | 26482 | 578781 | 49999739 |
Dialysis | 70.51 | 22.01 | 50 | 26554 | 9388 | 50569132 |
Joint swelling | 70.06 | 22.01 | 21 | 26583 | 245265 | 50333255 |
Skin induration | 66.84 | 22.01 | 32 | 26572 | 2879 | 50575641 |
Hyperparathyroidism | 63.03 | 22.01 | 29 | 26575 | 2385 | 50576135 |
Blood phosphorus abnormal | 62.66 | 22.01 | 15 | 26589 | 147 | 50578373 |
Sinusitis | 60.10 | 22.01 | 9 | 26595 | 170549 | 50407971 |
Hepatic enzyme increased | 59.77 | 22.01 | 3 | 26601 | 137377 | 50441143 |
Condition aggravated | 57.95 | 22.01 | 43 | 26561 | 297015 | 50281505 |
Product use issue | 57.25 | 22.01 | 6 | 26598 | 149469 | 50429051 |
Drug ineffective | 55.31 | 22.01 | 233 | 26371 | 819100 | 49759420 |
Arteriovenous fistula occlusion | 54.38 | 22.01 | 16 | 26588 | 363 | 50578157 |
Arthropathy | 54.12 | 22.01 | 9 | 26595 | 157897 | 50420623 |
Toxicity to various agents | 50.95 | 22.01 | 24 | 26580 | 212475 | 50366045 |
Systemic lupus erythematosus | 50.51 | 22.01 | 7 | 26597 | 140615 | 50437905 |
Parathyroid tumour malignant | 50.14 | 22.01 | 9 | 26595 | 15 | 50578505 |
Gastrostomy | 49.21 | 22.01 | 16 | 26588 | 510 | 50578010 |
Abdominal pain upper | 48.79 | 22.01 | 189 | 26415 | 159120 | 50419400 |
Skin hypertrophy | 47.69 | 22.01 | 26 | 26578 | 3069 | 50575451 |
Neutropenia | 47.36 | 22.01 | 10 | 26594 | 147955 | 50430565 |
Unevaluable event | 46.01 | 22.01 | 85 | 26519 | 45981 | 50532539 |
Skin fibrosis | 45.14 | 22.01 | 17 | 26587 | 842 | 50577678 |
Hypervolaemia | 44.88 | 22.01 | 61 | 26543 | 25438 | 50553082 |
Blue toe syndrome | 44.79 | 22.01 | 14 | 26590 | 392 | 50578128 |
Treatment failure | 44.67 | 22.01 | 9 | 26595 | 137628 | 50440892 |
Enteral nutrition | 44.50 | 22.01 | 9 | 26595 | 36 | 50578484 |
Therapeutic product effect decreased | 43.94 | 22.01 | 9 | 26595 | 136041 | 50442479 |
Peritonitis | 43.57 | 22.01 | 47 | 26557 | 15439 | 50563081 |
Skin tightness | 42.96 | 22.01 | 26 | 26578 | 3737 | 50574783 |
Stomatitis | 41.70 | 22.01 | 3 | 26601 | 101341 | 50477179 |
Injection site pain | 41.13 | 22.01 | 5 | 26599 | 111019 | 50467501 |
Glossodynia | 40.92 | 22.01 | 6 | 26598 | 115563 | 50462957 |
Hyperphosphataemia | 38.25 | 22.01 | 19 | 26585 | 1852 | 50576668 |
Swelling | 37.96 | 22.01 | 30 | 26574 | 200842 | 50377678 |
Rash | 37.66 | 22.01 | 112 | 26492 | 437359 | 50141161 |
Surgery | 37.02 | 22.01 | 61 | 26543 | 30144 | 50548376 |
Drug hypersensitivity | 36.58 | 22.01 | 47 | 26557 | 250963 | 50327557 |
Weight increased | 35.87 | 22.01 | 32 | 26572 | 201859 | 50376661 |
End stage renal disease | 35.21 | 22.01 | 27 | 26577 | 5710 | 50572810 |
Pelvic deformity | 34.32 | 22.01 | 10 | 26594 | 219 | 50578301 |
Thyroid operation | 33.31 | 22.01 | 9 | 26595 | 148 | 50578372 |
White blood cell count decreased | 33.27 | 22.01 | 10 | 26594 | 116712 | 50461808 |
Parathyroid disorder | 32.71 | 22.01 | 12 | 26592 | 552 | 50577968 |
Neuropathy peripheral | 32.08 | 22.01 | 6 | 26598 | 96751 | 50481769 |
Arteriovenous fistula site infection | 31.58 | 22.01 | 7 | 26597 | 47 | 50578473 |
Alanine aminotransferase increased | 30.34 | 22.01 | 5 | 26599 | 88354 | 50490166 |
Peritoneal dialysis complication | 30.24 | 22.01 | 14 | 26590 | 1167 | 50577353 |
Wrong technique in product usage process | 29.91 | 22.01 | 80 | 26524 | 55430 | 50523090 |
Contusion | 29.55 | 22.01 | 11 | 26593 | 112172 | 50466348 |
Cerebrovascular accident | 29.50 | 22.01 | 113 | 26491 | 94567 | 50483953 |
Parathyroid hyperplasia | 29.25 | 22.01 | 8 | 26596 | 138 | 50578382 |
Dyspnoea | 28.60 | 22.01 | 170 | 26434 | 547438 | 50031082 |
Joint contracture | 28.34 | 22.01 | 15 | 26589 | 1669 | 50576851 |
Product use in unapproved indication | 27.86 | 22.01 | 13 | 26591 | 115806 | 50462714 |
Treatment noncompliance | 26.85 | 22.01 | 53 | 26551 | 30097 | 50548423 |
Shunt occlusion | 26.35 | 22.01 | 10 | 26594 | 506 | 50578014 |
Cardiac operation | 26.10 | 22.01 | 17 | 26587 | 2778 | 50575742 |
Hyperparathyroidism tertiary | 26.09 | 22.01 | 5 | 26599 | 14 | 50578506 |
Malignant neoplasm progression | 25.40 | 22.01 | 3 | 26601 | 68121 | 50510399 |
Dysphagia | 25.37 | 22.01 | 94 | 26510 | 77424 | 50501096 |
Adjusted calcium decreased | 25.26 | 22.01 | 7 | 26597 | 127 | 50578393 |
Wound | 25.25 | 22.01 | 12 | 26592 | 105782 | 50472738 |
Headache | 25 | 22.01 | 160 | 26444 | 506375 | 50072145 |
Platelet count decreased | 24.70 | 22.01 | 11 | 26593 | 100715 | 50477805 |
Alopecia | 23.84 | 22.01 | 59 | 26545 | 244988 | 50333532 |
Aspartate aminotransferase increased | 23.50 | 22.01 | 6 | 26598 | 77992 | 50500528 |
Nephrocalcinosis | 23.25 | 22.01 | 11 | 26593 | 963 | 50577557 |
Chronic kidney disease-mineral and bone disorder | 23.24 | 22.01 | 6 | 26598 | 82 | 50578438 |
Arteriovenous fistula site haemorrhage | 23.00 | 22.01 | 7 | 26597 | 179 | 50578341 |
High turnover osteopathy | 22.50 | 22.01 | 5 | 26599 | 34 | 50578486 |
Arteriovenous fistula thrombosis | 22.49 | 22.01 | 7 | 26597 | 193 | 50578327 |
Wheezing | 22.48 | 22.01 | 3 | 26601 | 62044 | 50516476 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Product dose omission issue | 7475.63 | 21.36 | 2730 | 19041 | 93653 | 29459103 |
Hospitalisation | 6809.23 | 21.36 | 2125 | 19646 | 43863 | 29508893 |
Laboratory test abnormal | 5831.15 | 21.36 | 1539 | 20232 | 16646 | 29536110 |
Adverse drug reaction | 1051.37 | 21.36 | 457 | 21314 | 23563 | 29529193 |
Intentional product misuse | 726.86 | 21.36 | 399 | 21372 | 34262 | 29518494 |
Blood parathyroid hormone increased | 628.67 | 21.36 | 155 | 21616 | 1200 | 29551556 |
Blood parathyroid hormone abnormal | 474.19 | 21.36 | 85 | 21686 | 76 | 29552680 |
Arteriovenous fistula site complication | 375.68 | 21.36 | 82 | 21689 | 340 | 29552416 |
Adverse event | 219.50 | 21.36 | 138 | 21633 | 15153 | 29537603 |
Transplant | 212.08 | 21.36 | 57 | 21714 | 640 | 29552116 |
Blood calcium increased | 197.03 | 21.36 | 78 | 21693 | 3141 | 29549615 |
Hospice care | 190.88 | 21.36 | 87 | 21684 | 4981 | 29547775 |
Hypocalcaemia | 190.77 | 21.36 | 142 | 21629 | 20523 | 29532233 |
Parathyroidectomy | 183.39 | 21.36 | 35 | 21736 | 58 | 29552698 |
Blood parathyroid hormone decreased | 171.26 | 21.36 | 50 | 21721 | 774 | 29551982 |
Living in residential institution | 163.30 | 21.36 | 39 | 21732 | 259 | 29552497 |
Abdominal discomfort | 162.44 | 21.36 | 188 | 21583 | 47715 | 29505041 |
Blood calcium abnormal | 146.15 | 21.36 | 39 | 21732 | 425 | 29552331 |
Nausea | 140.80 | 21.36 | 499 | 21272 | 288756 | 29264000 |
Blood calcium decreased | 129.55 | 21.36 | 82 | 21689 | 9100 | 29543656 |
Rehabilitation therapy | 129.33 | 21.36 | 38 | 21733 | 602 | 29552154 |
Hypophagia | 128.06 | 21.36 | 113 | 21658 | 20759 | 29531997 |
Calciphylaxis | 120.11 | 21.36 | 40 | 21731 | 972 | 29551784 |
Blood phosphorus increased | 117.32 | 21.36 | 52 | 21719 | 2785 | 29549971 |
Renal transplant | 112.44 | 21.36 | 43 | 21728 | 1575 | 29551181 |
Vomiting | 109.77 | 21.36 | 374 | 21397 | 211886 | 29340870 |
Unevaluable investigation | 100.98 | 21.36 | 18 | 21753 | 15 | 29552741 |
Acute kidney injury | 90.83 | 21.36 | 41 | 21730 | 265226 | 29287530 |
Parathyroid tumour benign | 88.71 | 21.36 | 20 | 21751 | 99 | 29552657 |
Toxicity to various agents | 83.17 | 21.36 | 14 | 21757 | 173647 | 29379109 |
Death | 82.67 | 21.36 | 480 | 21291 | 341604 | 29211152 |
Hypercalcaemia | 78.07 | 21.36 | 69 | 21702 | 12690 | 29540066 |
Abdominal pain upper | 76.09 | 21.36 | 150 | 21621 | 60843 | 29491913 |
Malaise | 76.07 | 21.36 | 274 | 21497 | 159328 | 29393428 |
Hungry bone syndrome | 74.56 | 21.36 | 16 | 21755 | 60 | 29552696 |
Pyrexia | 69.29 | 21.36 | 66 | 21705 | 287556 | 29265200 |
Neutropenia | 66.74 | 21.36 | 9 | 21762 | 131702 | 29421054 |
Peritonitis bacterial | 63.25 | 21.36 | 44 | 21727 | 5712 | 29547044 |
Parathyroid disorder | 57.48 | 21.36 | 12 | 21759 | 38 | 29552718 |
Gastrointestinal disorder | 55.94 | 21.36 | 86 | 21685 | 28620 | 29524136 |
Surgery | 55.33 | 21.36 | 55 | 21716 | 11724 | 29541032 |
Gastrostomy | 51.27 | 21.36 | 19 | 21752 | 637 | 29552119 |
Decreased appetite | 50.32 | 21.36 | 226 | 21545 | 145116 | 29407640 |
Drug interaction | 48.98 | 21.36 | 44 | 21727 | 197341 | 29355415 |
Parathyroid tumour malignant | 48.76 | 21.36 | 9 | 21762 | 11 | 29552745 |
Nephrogenic systemic fibrosis | 47.73 | 21.36 | 32 | 21739 | 3910 | 29548846 |
Gastrointestinal tube insertion | 47.66 | 21.36 | 21 | 21750 | 1108 | 29551648 |
Parathyroid hyperplasia | 47.18 | 21.36 | 8 | 21763 | 3 | 29552753 |
Mastication disorder | 47.11 | 21.36 | 21 | 21750 | 1139 | 29551617 |
Fatigue | 41.67 | 21.36 | 109 | 21662 | 316712 | 29236044 |
Blood phosphorus abnormal | 41.54 | 21.36 | 11 | 21760 | 116 | 29552640 |
Adjusted calcium decreased | 41.01 | 21.36 | 7 | 21764 | 3 | 29552753 |
Unevaluable event | 40.35 | 21.36 | 76 | 21695 | 29775 | 29522981 |
Treatment noncompliance | 39.57 | 21.36 | 67 | 21704 | 24160 | 29528596 |
Dialysis | 39.55 | 21.36 | 43 | 21728 | 10165 | 29542591 |
Condition aggravated | 39.49 | 21.36 | 30 | 21741 | 146265 | 29406491 |
Hyperparathyroidism | 38.07 | 21.36 | 18 | 21753 | 1119 | 29551637 |
Gastric disorder | 37.88 | 21.36 | 43 | 21728 | 10661 | 29542095 |
Platelet count decreased | 37.60 | 21.36 | 15 | 21756 | 104657 | 29448099 |
Dyspnoea | 36.72 | 21.36 | 121 | 21650 | 326611 | 29226145 |
Leg amputation | 35.68 | 21.36 | 21 | 21750 | 2043 | 29550713 |
Overdose | 34.87 | 21.36 | 8 | 21763 | 79811 | 29472945 |
Hyperphosphataemia | 34.11 | 21.36 | 21 | 21750 | 2217 | 29550539 |
Alanine aminotransferase increased | 33.29 | 21.36 | 6 | 21765 | 70938 | 29481818 |
Disease progression | 32.39 | 21.36 | 10 | 21761 | 81906 | 29470850 |
Confusional state | 32.29 | 21.36 | 28 | 21743 | 127849 | 29424907 |
Shunt stenosis | 31.65 | 21.36 | 13 | 21758 | 576 | 29552180 |
White blood cell count decreased | 31.52 | 21.36 | 11 | 21760 | 83351 | 29469405 |
Brown tumour | 31.08 | 21.36 | 5 | 21766 | 0 | 29552756 |
Product use in unapproved indication | 30.30 | 21.36 | 13 | 21758 | 86862 | 29465894 |
Haemoglobin increased | 29.24 | 21.36 | 21 | 21750 | 2865 | 29549891 |
Shunt occlusion | 28.86 | 21.36 | 13 | 21758 | 723 | 29552033 |
Peritonitis | 28.29 | 21.36 | 44 | 21727 | 14780 | 29537976 |
Skin induration | 28.10 | 21.36 | 18 | 21753 | 2036 | 29550720 |
Anaemia | 28.01 | 21.36 | 67 | 21704 | 200884 | 29351872 |
Appetite disorder | 27.96 | 21.36 | 18 | 21753 | 2054 | 29550702 |
Neuropathy peripheral | 27.49 | 21.36 | 9 | 21762 | 71018 | 29481738 |
Pulmonary embolism | 27.42 | 21.36 | 11 | 21760 | 76523 | 29476233 |
Hyponatraemia | 27.20 | 21.36 | 8 | 21763 | 67625 | 29485131 |
Thyroid operation | 27.14 | 21.36 | 5 | 21766 | 6 | 29552750 |
Thrombocytopenia | 26.83 | 21.36 | 36 | 21735 | 134787 | 29417969 |
Vestibular neuronitis | 25.21 | 21.36 | 8 | 21763 | 166 | 29552590 |
Rhabdomyolysis | 24.81 | 21.36 | 7 | 21764 | 60801 | 29491955 |
Hyperparathyroidism secondary | 24.78 | 21.36 | 14 | 21757 | 1261 | 29551495 |
Wrong technique in product usage process | 24.30 | 21.36 | 64 | 21707 | 31364 | 29521392 |
Aspartate aminotransferase increased | 24.14 | 21.36 | 7 | 21764 | 59718 | 29493038 |
Pancytopenia | 23.80 | 21.36 | 16 | 21755 | 83152 | 29469604 |
Weight decreased | 23.75 | 21.36 | 47 | 21724 | 150858 | 29401898 |
Parathyroid gland enlargement | 23.14 | 21.36 | 7 | 21764 | 123 | 29552633 |
Drug effective for unapproved indication | 23.06 | 21.36 | 14 | 21757 | 1441 | 29551315 |
Product use issue | 22.77 | 21.36 | 5 | 21766 | 51439 | 29501317 |
Nephrocalcinosis | 22.46 | 21.36 | 10 | 21761 | 541 | 29552215 |
Tachycardia | 22.00 | 21.36 | 13 | 21758 | 72397 | 29480359 |
Dehydration | 21.47 | 21.36 | 32 | 21739 | 114716 | 29438040 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Laboratory test abnormal | 9690.85 | 16.86 | 2292 | 31984 | 21771 | 64442685 |
Hospitalisation | 5978.55 | 16.86 | 2014 | 32262 | 73193 | 64391263 |
Product dose omission issue | 3137.00 | 16.86 | 1678 | 32598 | 193069 | 64271387 |
Blood parathyroid hormone increased | 1010.43 | 16.86 | 251 | 34025 | 2883 | 64461573 |
Blood parathyroid hormone abnormal | 742.17 | 16.86 | 134 | 34142 | 232 | 64464224 |
Arteriovenous fistula site complication | 716.14 | 16.86 | 151 | 34125 | 765 | 64463691 |
Adverse drug reaction | 545.20 | 16.86 | 325 | 33951 | 45139 | 64419317 |
Nausea | 459.31 | 16.86 | 1168 | 33108 | 784632 | 63679824 |
Vomiting | 367.30 | 16.86 | 863 | 33413 | 550254 | 63914202 |
Decreased appetite | 351.78 | 16.86 | 575 | 33701 | 280714 | 64183742 |
Living in residential institution | 345.76 | 16.86 | 77 | 34199 | 524 | 64463932 |
Calciphylaxis | 309.93 | 16.86 | 101 | 34175 | 3211 | 64461245 |
Rehabilitation therapy | 298.95 | 16.86 | 82 | 34194 | 1416 | 64463040 |
Death | 280.68 | 16.86 | 718 | 33558 | 481987 | 63982469 |
Abdominal discomfort | 269.69 | 16.86 | 403 | 33873 | 181919 | 64282537 |
Hypocalcaemia | 269.03 | 16.86 | 203 | 34073 | 41550 | 64422906 |
Blood calcium increased | 251.75 | 16.86 | 112 | 34164 | 8430 | 64456026 |
Unevaluable investigation | 234.01 | 16.86 | 39 | 34237 | 28 | 64464428 |
Malaise | 218.19 | 16.86 | 578 | 33698 | 395669 | 64068787 |
Blood calcium abnormal | 197.30 | 16.86 | 57 | 34219 | 1197 | 64463259 |
Parathyroid tumour benign | 186.24 | 16.86 | 48 | 34228 | 644 | 64463812 |
Renal transplant | 180.16 | 16.86 | 61 | 34215 | 2187 | 64462269 |
Intentional product misuse | 177.09 | 16.86 | 205 | 34071 | 72090 | 64392366 |
Muscle spasms | 175.32 | 16.86 | 288 | 33988 | 140735 | 64323721 |
Blood phosphorus increased | 162.44 | 16.86 | 70 | 34206 | 4876 | 64459580 |
Blood calcium decreased | 159.59 | 16.86 | 122 | 34154 | 25432 | 64439024 |
Abdominal pain upper | 159.31 | 16.86 | 312 | 33964 | 174718 | 64289738 |
Hungry bone syndrome | 150.45 | 16.86 | 31 | 34245 | 137 | 64464319 |
Peritonitis bacterial | 149.87 | 16.86 | 80 | 34196 | 8963 | 64455493 |
Blood parathyroid hormone decreased | 141.65 | 16.86 | 72 | 34204 | 7294 | 64457162 |
Parathyroidectomy | 133.78 | 16.86 | 29 | 34247 | 171 | 64464285 |
Hypercalcaemia | 131.57 | 16.86 | 119 | 34157 | 31297 | 64433159 |
Nephrogenic systemic fibrosis | 126.30 | 16.86 | 62 | 34214 | 5830 | 64458626 |
Unevaluable event | 119.97 | 16.86 | 141 | 34135 | 50348 | 64414108 |
Hyperparathyroidism | 102.39 | 16.86 | 43 | 34233 | 2809 | 64461647 |
Toxicity to various agents | 97.06 | 16.86 | 36 | 34240 | 363477 | 64100979 |
Brown tumour | 92.21 | 16.86 | 17 | 34259 | 35 | 64464421 |
Surgery | 91.81 | 16.86 | 93 | 34183 | 28120 | 64436336 |
Adjusted calcium decreased | 88.81 | 16.86 | 20 | 34256 | 144 | 64464312 |
Pyrexia | 88.63 | 16.86 | 100 | 34176 | 558544 | 63905912 |
Dialysis | 84.76 | 16.86 | 71 | 34205 | 16849 | 64447607 |
Transplant | 83.05 | 16.86 | 27 | 34249 | 851 | 64463605 |
Febrile neutropenia | 82.99 | 16.86 | 4 | 34272 | 187653 | 64276803 |
Parathyroid tumour malignant | 81.98 | 16.86 | 15 | 34261 | 29 | 64464427 |
Skin induration | 80.82 | 16.86 | 41 | 34235 | 4134 | 64460322 |
Gastrointestinal tube insertion | 76.53 | 16.86 | 29 | 34247 | 1445 | 64463011 |
Neutropenia | 76.29 | 16.86 | 17 | 34259 | 239607 | 64224849 |
Gastric disorder | 75.15 | 16.86 | 85 | 34191 | 29112 | 64435344 |
Shunt occlusion | 74.20 | 16.86 | 27 | 34249 | 1200 | 64463256 |
Rheumatoid arthritis | 71.08 | 16.86 | 4 | 34272 | 164290 | 64300166 |
Hypophagia | 70.85 | 16.86 | 96 | 34180 | 39491 | 64424965 |
Parathyroid disorder | 69.81 | 16.86 | 20 | 34256 | 407 | 64464049 |
Gastrostomy | 68.13 | 16.86 | 24 | 34252 | 970 | 64463486 |
Condition aggravated | 66.58 | 16.86 | 60 | 34216 | 372366 | 64092090 |
Hyperphosphataemia | 65.34 | 16.86 | 35 | 34241 | 3946 | 64460510 |
Drug interaction | 63.93 | 16.86 | 59 | 34217 | 362024 | 64102432 |
Arthralgia | 60.90 | 16.86 | 88 | 34188 | 442172 | 64022284 |
Arteriovenous fistula occlusion | 60.65 | 16.86 | 19 | 34257 | 530 | 64463926 |
Fatigue | 59.52 | 16.86 | 202 | 34074 | 748528 | 63715928 |
Shunt stenosis | 59.06 | 16.86 | 22 | 34254 | 1045 | 64463411 |
Blood phosphorus abnormal | 58.72 | 16.86 | 16 | 34260 | 269 | 64464187 |
Acute kidney injury | 57.43 | 16.86 | 94 | 34182 | 449146 | 64015310 |
Peritonitis | 56.31 | 16.86 | 68 | 34208 | 24955 | 64439501 |
Skin hypertrophy | 55.82 | 16.86 | 33 | 34243 | 4496 | 64459960 |
Skin tightness | 55.59 | 16.86 | 34 | 34242 | 4927 | 64459529 |
Joint swelling | 54.67 | 16.86 | 23 | 34253 | 215359 | 64249097 |
Hypervolaemia | 52.70 | 16.86 | 82 | 34194 | 38203 | 64426253 |
Hepatic enzyme increased | 50.99 | 16.86 | 5 | 34271 | 129938 | 64334518 |
Leg amputation | 50.35 | 16.86 | 28 | 34248 | 3399 | 64461057 |
Diarrhoea | 50.19 | 16.86 | 595 | 33681 | 722109 | 63742347 |
Product use issue | 49.83 | 16.86 | 10 | 34266 | 151705 | 64312751 |
Peritoneal dialysis complication | 49.41 | 16.86 | 24 | 34252 | 2204 | 64462252 |
Sinusitis | 49.24 | 16.86 | 9 | 34267 | 145919 | 64318537 |
End stage renal disease | 48.46 | 16.86 | 42 | 34234 | 10433 | 64454023 |
Skin fibrosis | 45.78 | 16.86 | 20 | 34256 | 1439 | 64463017 |
Injection site pain | 44.47 | 16.86 | 4 | 34272 | 111404 | 64353052 |
Alanine aminotransferase increased | 43.95 | 16.86 | 10 | 34266 | 139021 | 64325435 |
Pelvic deformity | 43.93 | 16.86 | 10 | 34266 | 76 | 64464380 |
Parathyroid gland enlargement | 43.58 | 16.86 | 11 | 34265 | 135 | 64464321 |
White blood cell count decreased | 43.13 | 16.86 | 15 | 34261 | 157822 | 64306634 |
Appetite disorder | 42.87 | 16.86 | 32 | 34244 | 6429 | 64458027 |
Parathyroid hyperplasia | 41.92 | 16.86 | 11 | 34265 | 159 | 64464297 |
Platelet count decreased | 40.83 | 16.86 | 19 | 34257 | 167692 | 64296764 |
Cardiac operation | 40.00 | 16.86 | 26 | 34250 | 4188 | 64460268 |
Blue toe syndrome | 39.78 | 16.86 | 14 | 34262 | 564 | 64463892 |
High turnover osteopathy | 39.47 | 16.86 | 8 | 34268 | 32 | 64464424 |
Arteriovenous fistula thrombosis | 37.12 | 16.86 | 13 | 34263 | 516 | 64463940 |
Parathyroid haemorrhage | 36.81 | 16.86 | 6 | 34270 | 3 | 64464453 |
Arteriovenous fistula site infection | 36.48 | 16.86 | 10 | 34266 | 172 | 64464284 |
Therapeutic procedure | 36.46 | 16.86 | 14 | 34262 | 723 | 64463733 |
Stomatitis | 36.45 | 16.86 | 7 | 34269 | 109598 | 64354858 |
Angina pectoris | 34.59 | 16.86 | 75 | 34201 | 45006 | 64419450 |
Product use in unapproved indication | 34.55 | 16.86 | 26 | 34250 | 176592 | 64287864 |
Shunt infection | 34.30 | 16.86 | 9 | 34267 | 130 | 64464326 |
Drug ineffective | 33.49 | 16.86 | 286 | 33990 | 839961 | 63624495 |
Neuropathy peripheral | 32.39 | 16.86 | 11 | 34265 | 117514 | 64346942 |
Arthropathy | 32.18 | 16.86 | 12 | 34264 | 120955 | 64343501 |
Weight increased | 31.78 | 16.86 | 40 | 34236 | 213308 | 64251148 |
Wrong technique in product usage process | 31.76 | 16.86 | 91 | 34185 | 64883 | 64399573 |
Aspartate aminotransferase increased | 31.67 | 16.86 | 12 | 34264 | 119776 | 64344680 |
Joint contracture | 31.50 | 16.86 | 18 | 34258 | 2301 | 64462155 |
Nephrocalcinosis | 31.49 | 16.86 | 15 | 34261 | 1319 | 64463137 |
Hyperparathyroidism secondary | 31.42 | 16.86 | 18 | 34258 | 2312 | 64462144 |
Constipation | 31.36 | 16.86 | 219 | 34057 | 229118 | 64235338 |
Treatment noncompliance | 30.72 | 16.86 | 70 | 34206 | 43412 | 64421044 |
Fistula repair | 30.55 | 16.86 | 7 | 34269 | 55 | 64464401 |
Confusional state | 29.41 | 16.86 | 59 | 34217 | 261085 | 64203371 |
Blood pressure increased | 29.37 | 16.86 | 29 | 34247 | 172523 | 64291933 |
Rash | 29.13 | 16.86 | 135 | 34141 | 458414 | 64006042 |
Paraesthesia | 29.11 | 16.86 | 145 | 34131 | 134377 | 64330079 |
Dyspnoea | 28.88 | 16.86 | 244 | 34032 | 718430 | 63746026 |
Gastrointestinal disorder | 28.87 | 16.86 | 109 | 34167 | 89600 | 64374856 |
Haemoglobin increased | 28.50 | 16.86 | 23 | 34253 | 5178 | 64459278 |
Thyroid operation | 28.20 | 16.86 | 8 | 34268 | 157 | 64464299 |
Arrhythmia | 27.69 | 16.86 | 76 | 34200 | 52868 | 64411588 |
Toe amputation | 27.02 | 16.86 | 19 | 34257 | 3481 | 64460975 |
Arteriovenous fistula site haemorrhage | 26.70 | 16.86 | 9 | 34267 | 318 | 64464138 |
Therapeutic product effect decreased | 26.66 | 16.86 | 14 | 34262 | 115337 | 64349119 |
Hospice care | 26.39 | 16.86 | 26 | 34250 | 7599 | 64456857 |
Phosphaturic mesenchymal tumour | 26.16 | 16.86 | 4 | 34272 | 0 | 64464456 |
Lower respiratory tract infection | 25.82 | 16.86 | 9 | 34267 | 94605 | 64369851 |
Cerebrovascular accident | 25.44 | 16.86 | 142 | 34134 | 137441 | 64327015 |
Psoriasis | 25.11 | 16.86 | 4 | 34272 | 71699 | 64392757 |
Parathyroid gland operation | 24.67 | 16.86 | 5 | 34271 | 20 | 64464436 |
Intentional product use issue | 24.47 | 16.86 | 10 | 34266 | 95354 | 64369102 |
Treatment failure | 24.42 | 16.86 | 16 | 34260 | 116800 | 64347656 |
Hypercalciuria | 24.23 | 16.86 | 9 | 34267 | 424 | 64464032 |
Fibrosis | 24.01 | 16.86 | 20 | 34256 | 4708 | 64459748 |
Medical procedure | 23.97 | 16.86 | 8 | 34268 | 274 | 64464182 |
Hepatic cyst infection | 23.79 | 16.86 | 7 | 34269 | 157 | 64464299 |
Overdose | 23.67 | 16.86 | 30 | 34246 | 159536 | 64304920 |
Neoplasm malignant | 23.60 | 16.86 | 45 | 34231 | 24643 | 64439813 |
Pain | 23.53 | 16.86 | 185 | 34091 | 553326 | 63911130 |
Mucosal inflammation | 23.06 | 16.86 | 3 | 34273 | 62581 | 64401875 |
Adverse event | 23.00 | 16.86 | 59 | 34217 | 39430 | 64425026 |
Hyperparathyroidism tertiary | 22.92 | 16.86 | 4 | 34272 | 5 | 64464451 |
Thrombosis in device | 22.79 | 16.86 | 20 | 34256 | 5051 | 64459405 |
Chronic kidney disease-mineral and bone disorder | 22.78 | 16.86 | 9 | 34267 | 502 | 64463954 |
Intracardiac mass | 22.41 | 16.86 | 6 | 34270 | 94 | 64464362 |
Hypotension | 22.18 | 16.86 | 304 | 33972 | 380670 | 64083786 |
Skin hyperpigmentation | 22.05 | 16.86 | 22 | 34254 | 6529 | 64457927 |
Wheezing | 21.42 | 16.86 | 8 | 34268 | 80571 | 64383885 |
Rhabdomyolysis | 21.39 | 16.86 | 11 | 34265 | 91715 | 64372741 |
Blood pressure abnormal | 21.39 | 16.86 | 32 | 34244 | 14403 | 64450053 |
Pericarditis | 20.77 | 16.86 | 4 | 34272 | 62512 | 64401944 |
Pancytopenia | 20.18 | 16.86 | 28 | 34248 | 143281 | 64321175 |
Syncope | 20.07 | 16.86 | 33 | 34243 | 157602 | 64306854 |
Foot amputation | 20.04 | 16.86 | 9 | 34267 | 692 | 64463764 |
Intermittent claudication | 19.98 | 16.86 | 15 | 34261 | 3039 | 64461417 |
Deep vein thrombosis | 19.91 | 16.86 | 16 | 34260 | 105166 | 64359290 |
Glossodynia | 19.75 | 16.86 | 5 | 34271 | 64691 | 64399765 |
Parathyroid cyst | 19.62 | 16.86 | 3 | 34273 | 0 | 64464456 |
Drug hypersensitivity | 19.58 | 16.86 | 63 | 34213 | 237752 | 64226704 |
Liver function test abnormal | 19.32 | 16.86 | 4 | 34272 | 59397 | 64405059 |
Swelling | 19.07 | 16.86 | 35 | 34241 | 160183 | 64304273 |
Cardiac disorder | 18.94 | 16.86 | 69 | 34207 | 55747 | 64408709 |
Blood phosphorus decreased | 18.91 | 16.86 | 19 | 34257 | 5686 | 64458770 |
Systemic lupus erythematosus | 18.56 | 16.86 | 9 | 34267 | 77603 | 64386853 |
Renal cyst infection | 18.43 | 16.86 | 6 | 34270 | 190 | 64464266 |
Anaemia | 18.27 | 16.86 | 122 | 34154 | 378558 | 64085898 |
Gangrene | 18.26 | 16.86 | 21 | 34255 | 7317 | 64457139 |
Oxygen saturation decreased | 18.24 | 16.86 | 18 | 34258 | 107158 | 64357298 |
Calcinosis | 18.22 | 16.86 | 12 | 34264 | 1976 | 64462480 |
Joint range of motion decreased | 18.17 | 16.86 | 35 | 34241 | 19308 | 64445148 |
Anaphylactic reaction | 17.94 | 16.86 | 7 | 34269 | 68657 | 64395799 |
Product dispensing issue | 17.93 | 16.86 | 5 | 34271 | 92 | 64464364 |
Extremity contracture | 17.86 | 16.86 | 11 | 34265 | 1614 | 64462842 |
Oncocytoma | 17.62 | 16.86 | 4 | 34272 | 30 | 64464426 |
Nasal congestion | 17.48 | 16.86 | 5 | 34271 | 59653 | 64404803 |
Vestibular neuronitis | 17.42 | 16.86 | 8 | 34268 | 648 | 64463808 |
Poor peripheral circulation | 17.22 | 16.86 | 14 | 34262 | 3186 | 64461270 |
Blood glucose decreased | 17.20 | 16.86 | 38 | 34238 | 23085 | 64441371 |
Hyponatraemia | 17.13 | 16.86 | 33 | 34243 | 148306 | 64316150 |
Blood cholesterol increased | 17.07 | 16.86 | 3 | 34273 | 50063 | 64414393 |
Depression | 16.93 | 16.86 | 46 | 34230 | 183245 | 64281211 |
None
Source | Code | Description |
---|---|---|
ATC | H05BX01 | SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS CALCIUM HOMEOSTASIS ANTI-PARATHYROID AGENTS Other anti-parathyroid agents |
FDA MoA | N0000020081 | Increased Calcium-sensing Receptor Sensitivity |
MeSH PA | D057966 | Calcimimetic Agents |
MeSH PA | D000077264 | Calcium-Regulating Hormones and Agents |
MeSH PA | D006727 | Hormone Antagonists |
FDA EPC | N0000175902 | Calcium-sensing Receptor Agonist |
CHEBI has role | CHEBI:48525 | calcimimetics |
CHEBI has role | CHEBI:50183 | P450 inhibitors |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Hypercalcemia due to Primary Hyperparathyroidism | indication | ||
Hyperparathyroidism Secondary to Chronic Renal Failure with Dialysis | indication | ||
Parathyroid Carcinoma with Hypercalcemia | indication | ||
Hypophosphatemia | contraindication | 4996001 | |
Hypocalcemia | contraindication | 5291005 | |
Low blood pressure | contraindication | 45007003 | |
Chronic heart failure | contraindication | 48447003 | |
Seizure disorder | contraindication | 128613002 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Adynamic bone disease | contraindication | 236552002 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 8.69 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
EQ 30MG BASE | SENSIPAR | AMGEN | N021688 | March 8, 2004 | RX | TABLET | ORAL | 7829595 | Sept. 22, 2026 | METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF TREATING HYPERCALCEMIA |
EQ 60MG BASE | SENSIPAR | AMGEN | N021688 | March 8, 2004 | RX | TABLET | ORAL | 7829595 | Sept. 22, 2026 | METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF TREATING HYPERCALCEMIA |
EQ 90MG BASE | SENSIPAR | AMGEN | N021688 | March 8, 2004 | RX | TABLET | ORAL | 7829595 | Sept. 22, 2026 | METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF TREATING HYPERCALCEMIA |
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Extracellular calcium-sensing receptor | GPCR | POSITIVE ALLOSTERIC MODULATOR | EC50 | 7.70 | CHEMBL | CHEMBL | |||
Cytochrome P450 2D6 | Enzyme | IC50 | 7.30 | CHEMBL | |||||
Glycine receptor subunit alpha-1 | Ion channel | EC50 | 6.49 | CHEMBL | |||||
Metabotropic glutamate receptor 5 | GPCR | ALLOSTERIC MODULATOR | Ki | 4.35 | IUPHAR |
ID | Source |
---|---|
4021430 | VUID |
N0000148841 | NUI |
D03504 | KEGG_DRUG |
364782-34-3 | SECONDARY_CAS_RN |
384379 | RXNORM |
4021430 | VANDF |
C1337242 | UMLSCUI |
CHEBI:48390 | CHEBI |
YP4 | PDB_CHEM_ID |
CHEMBL1201284 | ChEMBL_ID |
CHEMBL1200776 | ChEMBL_ID |
DB01012 | DRUGBANK_ID |
D000069449 | MESH_DESCRIPTOR_UI |
156419 | PUBCHEM_CID |
3308 | IUPHAR_LIGAND_ID |
8287 | INN_ID |
UAZ6V7728S | UNII |
18133 | MMSL |
303128 | MMSL |
49840 | MMSL |
d05218 | MMSL |
008595 | NDDF |
008596 | NDDF |
409391006 | SNOMEDCT_US |
409392004 | SNOMEDCT_US |
426512007 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Cinacalcet | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7067 | TABLET, FILM COATED | 30 mg | ORAL | ANDA | 25 sections |
Cinacalcet | Human Prescription Drug Label | 1 | 16714-078 | TABLET, FILM COATED | 30 mg | ORAL | ANDA | 27 sections |
Cinacalcet | Human Prescription Drug Label | 1 | 16714-079 | TABLET, FILM COATED | 60 mg | ORAL | ANDA | 27 sections |
Cinacalcet | Human Prescription Drug Label | 1 | 16714-080 | TABLET, FILM COATED | 90 mg | ORAL | ANDA | 27 sections |
CINACALCET | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16729-440 | TABLET, FILM COATED | 30 mg | ORAL | ANDA | 25 sections |
CINACALCET | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16729-441 | TABLET, FILM COATED | 60 mg | ORAL | ANDA | 25 sections |
CINACALCET | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16729-442 | TABLET, FILM COATED | 90 mg | ORAL | ANDA | 25 sections |
Cinacalcet | Human Prescription Drug Label | 1 | 31722-103 | TABLET, FILM COATED | 30 mg | ORAL | ANDA | 29 sections |
Cinacalcet | Human Prescription Drug Label | 1 | 31722-104 | TABLET, FILM COATED | 60 mg | ORAL | ANDA | 29 sections |
Cinacalcet | Human Prescription Drug Label | 1 | 31722-105 | TABLET, FILM COATED | 90 mg | ORAL | ANDA | 29 sections |
Cinacalcet | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-459 | TABLET, FILM COATED | 30 mg | ORAL | ANDA | 25 sections |
Cinacalcet | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-460 | TABLET, FILM COATED | 60 mg | ORAL | ANDA | 25 sections |
Cinacalcet | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-461 | TABLET, FILM COATED | 90 mg | ORAL | ANDA | 25 sections |
Cinacalcet | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42543-961 | TABLET, FILM COATED | 30 mg | ORAL | ANDA | 23 sections |
Cinacalcet | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42543-962 | TABLET, FILM COATED | 60 mg | ORAL | ANDA | 23 sections |
Cinacalcet | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42543-963 | TABLET, FILM COATED | 90 mg | ORAL | ANDA | 23 sections |
Cinacalcet | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43598-367 | TABLET | 30 mg | ORAL | ANDA | 24 sections |
Cinacalcet | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43598-368 | TABLET | 60 mg | ORAL | ANDA | 24 sections |
Cinacalcet | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43598-369 | TABLET | 90 mg | ORAL | ANDA | 24 sections |
Cinacalcet | Human Prescription Drug Label | 1 | 47335-379 | TABLET, FILM COATED | 30 mg | ORAL | ANDA | 27 sections |
Cinacalcet | Human Prescription Drug Label | 1 | 47335-380 | TABLET, FILM COATED | 60 mg | ORAL | ANDA | 27 sections |
Cinacalcet | Human Prescription Drug Label | 1 | 47335-600 | TABLET, FILM COATED | 90 mg | ORAL | ANDA | 27 sections |
Sensipar | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-3529 | TABLET, COATED | 30 mg | ORAL | NDA | 28 sections |
Sensipar | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-4470 | TABLET, COATED | 30 mg | ORAL | NDA | 26 sections |
Cinacalcet | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50268-153 | TABLET | 30 mg | ORAL | ANDA | 24 sections |
Cinacalcet | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-295 | TABLET, FILM COATED | 30 mg | ORAL | ANDA | 23 sections |
Cinacalcet | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-296 | TABLET, FILM COATED | 60 mg | ORAL | ANDA | 23 sections |
Cinacalcet | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-297 | TABLET, FILM COATED | 90 mg | ORAL | ANDA | 23 sections |
Sensipar | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53808-0577 | TABLET, COATED | 30 mg | ORAL | NDA | 26 sections |
Sensipar | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53808-0578 | TABLET, COATED | 60 mg | ORAL | NDA | 26 sections |